BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27174585)

  • 1. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.
    Wang SA; Tam W; Tsai AG; Arber DA; Hasserjian RP; Geyer JT; George TI; Czuchlewski DR; Foucar K; Rogers HJ; Hsi ED; Bryan Rea B; Bagg A; Dal Cin P; Zhao C; Kelley TW; Verstovsek S; Bueso-Ramos C; Orazi A
    Mod Pathol; 2016 Aug; 29(8):854-64. PubMed ID: 27174585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.
    Wang SA; Hasserjian RP; Tam W; Tsai AG; Geyer JT; George TI; Foucar K; Rogers HJ; Hsi ED; Rea BA; Bagg A; Bueso-Ramos CE; Arber DA; Verstovsek S; Orazi A
    Haematologica; 2017 Aug; 102(8):1352-1360. PubMed ID: 28495918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing.
    Lee JS; Seo H; Im K; Park SN; Kim SM; Lee EK; Kim JA; Lee JH; Kwon S; Kim M; Koh I; Hwang S; Park HW; Kang HR; Park KS; Kim JH; Lee DS
    PLoS One; 2017; 12(10):e0185602. PubMed ID: 29088303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing.
    Pardanani A; Lasho T; Wassie E; Finke C; Zblewski D; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Leukemia; 2016 Sep; 30(9):1924-6. PubMed ID: 27125206
    [No Abstract]   [Full Text] [Related]  

  • 5. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
    Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
    Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Diagnostic Work-Up of Hypereosinophilia.
    Wang SA
    Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
    Odinius TO; Buschhorn L; Wagner C; Hauch RT; Dill V; Dechant M; Buck MC; Shoumariyeh K; Moog P; Schwaab J; Reiter A; Brockow K; Götze K; Bassermann F; Höckendorf U; Branca C; Jost PJ; Jilg S
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):331-340. PubMed ID: 34654952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The hypereosinophilic variant of Ph'-positive chronic myeloleukemia].
    Khoroshko ND; Mokeeva RA; Turkina AG; Arkhipova NV; Semenova EA; Zakharova AV; Kobzev IuN; Sakhibzadaeva KK; Tagiev AF
    Ter Arkh; 1998; 70(7):29-37. PubMed ID: 9742632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic.
    Morsia E; Reichard K; Pardanani A; Tefferi A; Gangat N
    Am J Hematol; 2020 Jul; 95(7):E172-E174. PubMed ID: 32243620
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation.
    Helbig G; Soja A; Bartkowska-Chrobok A; Kyrcz-Krzemień S
    Am J Hematol; 2012 Jun; 87(6):643-5. PubMed ID: 22473587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
    Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
    Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome.
    Andersen CL; Nielsen HM; Kristensen LS; Søgaard A; Vikeså J; Jønson L; Nielsen FC; Hasselbalch H; Bjerrum OW; Punj V; Grønbæk K
    Oncotarget; 2015 Dec; 6(38):40588-97. PubMed ID: 26497854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
    Helbig G; Klion AD
    Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
    Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
    Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The international consensus classification of eosinophilic disorders and systemic mastocytosis.
    Wang SA; Orazi A; Gotlib J; Reiter A; Tzankov A; Hasserjian RP; Arber DA; Tefferi A
    Am J Hematol; 2023 Aug; 98(8):1286-1306. PubMed ID: 37283522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.